UAE – AstraZeneca has introduced its revolutionary cancer medication, IMJUDO, for patients in the United Arab Emirates.
The United Arab Emirates becomes the first country in the Middle East to approve the use of this highly cancer medication, a possible step forward in fighting the highly invasive disease.
The strategic agreement will focus on specific areas of cooperation between both parties to tackle non-communicable diseases including cancer.
AstraZeneca’s cancer drug is recommended for use in the treatment of metastatic non-small cell lung cancer, hepatobiliary cancers, and other types of cancer.
It is the first and only approved therapy in combination with IMFINZI, a human monoclonal antibody, having 3-year data in first-line advanced or unresectable hepatocellular carcinoma.
Following the directives of the Ministry of Health and Prevention (MoHAP), AstraZeneca is gearing up to enhance the availability and accessibility of IMJUDO in the UAE.
In an official note, AstraZeneca said: “The launch of IMJUDO cements the UAE’s pledge to advancing oncology care and offers patients and families access to cutting-edge therapies.”
“The launch of IMJUDO in the UAE comes in line with its growing focus on quality cancer care, with over 30 cancer centres and clinics established across the country,” the company announced.
It is poised to extend progression-free survival and overall survival rates, empower cancer patients with better treatment outcomes, and, ultimately, maximize patients’ quality of life.
The drug launch follows successful clinical trials showing the efficacy and tolerability of IMJUDO in combination with various cancer immunotherapies.
AstraZeneca has reiterated its commitment to transform the landscape of comprehensive cancer care in the UAE and the Middle East by launching this innovative medication for cancer patients.
Commenting on the drug launch, Sameh El Fangary, Country President for GCC and Pakistan at AstraZeneca, stated: “Our mission is to continue to collaborate with our partners to transform health and wellbeing for people, society, and the planet.”
Moreover, AstraZeneca has organized a series of workshops and sessions to introduce the new cancer medication to healthcare experts in the UAE.
These medical education programs drew the participation of over 100 healthcare professionals working at major cancer healthcare facilities across the country.
It offered an ideal opportunity for national, regional, and international healthcare experts to showcase the revolutionary data of using immunotherapy combinations to combat cancer.
By combining cancer immunotherapies, healthcare experts can potentially improve the survival rates of patients with liver and lung cancer patients.
Its promising results suggest a new effective approach to treating liver and lung cancers, where the medications are tailored to the individual needs of patients.
What’s more, AstraZeneca is closely working with healthcare providers, policymakers, and patient advocacy groups to raise awareness about IMJUDO and its role in transforming cancer care.
“This collaboration highlights our unwavering commitment to accelerate the latest innovation to the UAE and to the region, inspired by our strategic focus to eliminate cancer-related deaths,” underlined Sameh El Fangary.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
